Infertility
Conditions
Brief summary
Estradiol valerate in the form of cycloprogenova™ (white tablet only) was started on day 2 or 3 of cycle with oral dose 4 mg divided on 2 doses in addition to Aspocid 75 mg once daily with folic acid 500 mcg once daily.
Detailed description
U/S was done on day 9 or 10 of cycle to assess endometrial thickness, then every other day until endometrial thickness of 8 mm or more is reached and when endometrial thickness reaches 8 mm or more FET was planned. Progesterone in the form of prontogest™ 400 mg vaginal suppository twice dTwo to Four Day 5 Embryos was transferred
Interventions
DRUGAgonist (decapeptyl )
giving agonist
DRUGHCG ( eg. Choriomon )
giving HCG
Sponsors
Cairo University
Aljazeera Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
Yes
Inclusion criteria
* PCOS patients according to Rotterdam criteria * Female age between 20 and 40 years. * Primary or secondary infertility. * Body mass index (BMI) between 18 and 40 kg/m2.
Exclusion criteria
* Ovarian endometriosis. * Ovarian cysts before induction. * Known uncontrolled endocrinal abnormalities (like hypo or hyperthyroidism)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the number of good quality embryos | within 5 months | how many good quality embryos |
Countries
Egypt
Contacts
Primary ContactMahmoud Alalfy
Outcome results
None listed